CHARMING MEDICAL LTD-AMCTA
ASignal's systematic analysis rates MCTA as Bearish.
Reflects the latest available analysis · analyzed Oct 2, 2026
The case on MCTA
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Gross margin of 96.36% indicates strong pricing power
- Debt-to-equity ratio of 0.18x suggests low leverage risk
- Current ratio of 1.89x indicates solid short-term liquidity
- Negative operating cash flow of $-1.22M
- Negative free cash flow of $-507,041
- Profit margin of -0.47% indicates unprofitability
- Revenue growth of -18.90% year-over-year
- Earnings growth of -93.80% year-over-year
- Extremely high P/E ratio of 419.36x and P/B of 97.20x
See the full verdict on MCTA
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes MCTA
Most investors never get a second opinion, let alone several. ASignal runs MCTA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.